Arkolith/Insider Trading/CYCC/Form 4

McBarron Paul

See Remarks, DirectorCyclacel Pharmaceuticals, Inc. (CYCC) · full profile →Form 4 · filed Dec 26, 2023
Net Buying
Open-Market Buys
$6K
Open-Market Sells
$0
Net Open-Market Flow
$6K
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 21, 2023Buy(P)2K$3.32$6K33K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 21, 2023Buy(P)2K—$02K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-23-129186) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML